scholarly journals Study of risk factors for erectile dysfunction in patients with type 2 diabetes mellitus: Correlation to serum testosterone level

2018 ◽  
Vol 54 (4) ◽  
pp. 319-321 ◽  
Author(s):  
Mohamed Abdelraouf Korani ◽  
Ahmed Sonbol
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Testosterone Level ◽  
Serum Testosterone ◽  
Serum Testosterone Level

scholarly journals Risk Perception for Developing Erectile Dysfunction among Malaysian Men with Type 2 Diabetes Mellitus

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Anuar Mohamad ◽  
Hizlinda Tohid ◽  
Saharuddin Ahmad ◽  
Seng Fah Tong ◽  
Mahadir Ahmad
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Risk Perception ◽  
Tertiary Education ◽  
Health Clinic ◽  
P Value

Risk perception for developing erectile dysfunction (ED) is an appreciation of the susceptibility to having ED and its severity. This study examined this risk perception and its associated factors among 180 men with type 2 diabetes mellitus (T2DM), who claimed not to have ED. This cross sectional study was conducted at a public health clinic using a validated self-administered questionnaire, which assessed participant characteristics, perceived susceptibility to developing ED, perceived severity of ED, and knowledge on risk factors for ED. About 71.1% had an inaccurate perception of susceptibility to developing ED and their perception on its severity was moderate (median (IQR) score: 10.0 (6.0); range score: 3–15; midpoint: 9). In multiple linear regression, having ED symptoms (p-value < 0.001) and secondary (p-value = 0.045) or tertiary education (p-value: 0.022) significantly contributed to a higher perception of susceptibility. A higher perception of severity was significantly found in Malays (p-value < 0.001), the employed (p-value = 0.026), and those with better knowledge on risk factors for ED (p-value < 0.001). Risk perception for developing ED among men with T2DM appears poor and it was significantly influenced by sociocultural factors, educational attainment, ED symptoms, and knowledge on risk factors for ED. Thus, to improve their risk perception, they should be provided appropriate counseling and education.

scholarly journals Age-related androgen deficiency and erectile dysfunction in men of the reproductive age presenting with type 2 diabetes mellitus

2013 ◽  
Vol 59 (1) ◽  
pp. 3-7
Author(s):  
R M Mamedgasanov ◽  
T V Mekhtiev
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Cardiovascular Diseases ◽  
Androgen Deficiency ◽  
Congenital Diseases ◽  
Age Related

Aim of the study. To detect hypogonadism and elucidate its relationship with erectile dysfunction (ED) and the main risk factors of cardiovascular diseases (CVD) among the patients with type 2 diabetes mellitus (DM2). Materials and methods. This clinical epidemiological study included 261 men with DM2 at the age varying from 30 to 59 years. The following exclusion criteria were used: type 1 diabetes mellitus, primary hypogonadism, drug-induced and congenital diseases accompanied by hypogonadism, oncological and cardiovascular diseases. All the patients underwent routine clinical examination, questionnaire and instrumental studies, laboratory analysis including assays for sex hormones. Results. Hypogonadism was diagnosed based on the results of all above studies in 114 (43.7%) men presenting with type 2 diabetes mellitus whereas the AMS questionnaire revealed a 10% higher incidence of age-related hypogonadism (in 141 or 54% subjects). It means that the incidence of hypogonadism increases with age both among the patients with DM2 and in the general male population. For example, only 17.5% of the men at the age of 30-39 years suffered hypogonadism compared with thrice this frequency in the groups of 40-49 and 50-59 year-old subjects. The summarized international erectile function index (IEFI) in the patients with hypogonadism and DM2 was 14.2±0.5 compared with 19.0±0.9 in the group without hypogonadism (p<0.001). Erectile dysfunction was diagnosed in 42 (28.6%) of the 147 patients with DM2 in the absence of hypogonadism whereas all the patients with hypogonadism suffered ED. The groups of the patients presenting with DM2 and hypogonadism and with DM2 without hypogonadism were not significantly different in terms of the number of smokers and hypokinetic subjects (roughly 70%). A similar tendency was documented in the occurrence of such parameters as waist circumference and serum triglycerides levels whereas the total and LDLP cholesterol levels, arterial pressure and body mass index were significantly higher in the patients with hypogonadism. Conclusion. Almost each second man with type 2 diabetes mellitus suffers hypogonadism and the number of such patients increases with age. The presence of DM2 increases the risk of development of ED. Also, the probability of ED and its severity increase under effect of androgen deficiency. The combination of DM2 and hypogonadism promotes manifestation of the main risk factors of cardiovascular diseases.

scholarly journals Independent Predictors of Erectile Dysfunction in Type 2 Diabetes Mellitus: Is It True What They Say about Risk Factors?

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Faranak Sharifi ◽  
Mohammad Asghari ◽  
Yahya Jaberi ◽  
Oveis Salehi ◽  
Fatemeh Mirzamohammadi
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Profile ◽  
Glycosylated Hemoglobin ◽  
Multivariate Logistic Regression Analysis ◽  
Serum Testosterone Level ◽  
Channel Blockers

Introduction. The aim of this study was to evaluate the independent predictors of ED in adult men with type 2 diabetes mellitus (T2DM). Methods. We have recruited 200 T2DM patients referred to our center between March 1, 2009 and March 1, 2010. All the patients were scored with the International Index of Erectile Function (IIEF)-5 questionnaires. Contribution of age, body mass index (BMI), smoking, blood pressure, lipid profile, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), free testosterone concentration, and duration of diabetes to risk of ED were evaluated. Results. Of 200 men with T2DM, 59.5% had ED (95%CI: 52%–67%). A negative significant correlation was found between potency score and HbA1c (r: 0.20,P: 0.01), FPG (r: 0.17, P: 0.03) and SBP (r: 0.18, P: 0.02) but not between other risk factors such as lipid profile, BMI, and serum testosterone level. By using multivariate logistic regression analysis, we found out that the only two independent predictors of ED in these group of patients are age (OR: 2.8, P: 0.01), and taking calcium channel blockers (CCB) (OR: 4.1, P: 0.01). Conclusions. Aging and taking CCB were the only two major predictors for ED but surprisingly other metabolic or sexual covariates in this study did not have predictive value for ED risk in T2DM patients.

scholarly journals Total Serum Testosterone Level in Obese Patients with Type -2 Diabetes Mellitus

2021 ◽  
Vol 11 (3) ◽  
Author(s):  
Mohamed Khier FE ◽  
Shaza Elawad ◽  
Nisreen Daffa Alla ◽  
Badi RM
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Symptoms ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Total Serum ◽  
Morbidly Obese ◽  
Testosterone Replacement Therapy

Both obesity and type 2 diabetes mellitus (T2DM) are independently associated with reduced serum testosterone. The additive effect of obesity and T2DM on reducing testosterone levels need to be investigated. Their combined additive effects may place obese T2DM patients at higher risk of decreased testosterone and the associated increased morbidity and mortality. The aim of this study is to screen obese T2DM patients for biochemical hypogonadism regardless of the presence of overt clinical symptoms to consider testosterone replacement therapy. About 152 adult male aged 40 to 68 years (age group and gender????) with T2DM were recruited through simple random sampling. The study participants were grouped based on their BMI into lean (n=48); overweight (n=57), obese (n=37) and morbidly obese (n=11). TST, BMI and waist circumference (WC) were measured in all patients and luteinizing hormone (LH) was measured in 103 of them. Low TST was defined as TST<9nmol/L and the normal range for LH was 1.7-11.2mIU/ml. Mean TST in lean T2DM patients was 15.61± 6.0 nmol/l. TST levels were significantly lower in obese and morbidly obese groups compared with the lean group (P=0.003 and 0.015 respectively). TST negatively correlated with BMI (r= -0.29, P<0.001) and WC (r= -0.21, P<0.009). Overall, 19.7% of T2DM patients had low TST. The prevalence of low TST increased from 14.9% in lean, to 21.1% in overweight, to 21.6% in obese, to 27.3% in morbidly obese T2DM patients, (P=0.74). LH was inappropriately normal in 95% (19/20) of patients with low TST. Obese T2DM patients had reduced TST levels and a higher prevalence of reduced TST compared to lean patients. TST negatively correlated with BMI and WC. Therefore, screening obese T2DM patients for testosterone deficiency should be considered.

Sign in / Sign up

Export Citation Format

Share Document